Focal adhesion kinase (FAK) inhibitor‐defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma (ESCC) cells via effective blockade of PI3K/AKT axis and downstream molecular network-Reference-Cited by-同舟云学术

Focal adhesion kinase (FAK) inhibitor‐defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma (ESCC) cells via effective blockade of PI3K/AKT axis and downstream molecular network

Published:2020-12-06 Issue:2 Volume:60 Page:113-124
ISSN:0899-1987
Container-title:Molecular Carcinogenesis
language:en
Short-container-title:Molecular Carcinogenesis

Author:

Zhang Lingyuan¹,Zhao Di¹,Wang Yan¹,Zhang Weimin¹,Zhang Jing¹,Fan Jiawen¹,Zhan Qimin¹²³,Chen Jie¹^ORCID

Affiliation:

1. Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Molecular Oncology Peking University Cancer Hospital & Institute Beijing China

2. Institute of Cancer Research Shenzhen Bay Laboratory Shenzhen China

3. Research Unit of Molecular Cancer Research Chinese Academy of Medical Sciences China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Molecular Biology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mc.23273

Reference27 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries